Menu Back toSESSION 3 : Strategy for Comparability Study on Change Management of Cell Therapy Products and Gene Therapy Products

5th DIA Cell and Gene Therapy Products Symposium in Japan

This event is now offered in a new entirely virtual format.

All prices are exclusive of 10% Japanese consumption tax

SESSION 3 : Strategy for Comparability Study on Change Management of Cell Therapy Products and Gene Therapy Products

Session Chair(s)

Takehiko  Kaneko, MD

Takehiko Kaneko, MD

  • Senior Vice President, Chief Medical Officer (CMO), Head of R&D
  • Heartseed Inc., Japan
Kazunobu  Oyama, PhD

Kazunobu Oyama, PhD

  • Daiichi Sankyo Co., Ltd., Japan

Speaker(s)

Keigo  Kawabe

Change Control Strategy and Comparability Evaluation for Cell Therapy Products

Keigo Kawabe

  • Director, Quality Assurance Group, Regenerative & Cellular Medicine Office
  • Sumitomo Dainippon Pharma Co., Ltd., Japan
Kazumi  Sawaguchi, PhD

Challenge to comparability evaluation and change control of Cell Therapy Product

Kazumi Sawaguchi, PhD

  • Head of Regulatory Affairs and Quality Compliance
  • SanBio Company Limited, Japan
Mats  Lundgren

GMP quality processing of Adeno Associated viral vectors

Mats Lundgren

  • Customer Applications Director
  • Cytiva, Sweden

Contact us


Please contact DIA Japan for further information.

Send Email
+81.3.6214.0574